Attovia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Attovia Therapeutics (ATTO).

Price Target Range — 1 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingOutperform# Analysts5Avg. Consensus PT$42Upside to Avg. PT+137.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Citigroup	Yigal Nochomovitz	Initiate	Buy	$30
Aug 31, 2026	LifeSci Capital	—	Initiate	Outperform	$45
Aug 31, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$52
Aug 31, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$45
Aug 31, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$39

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Buy rating and announces Price Target of $30.

Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

LifeSci Capital initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.

Benzinga Newsdesk

PRO
RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI

Avi Kapoor

PRO
Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39

Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Overweight rating and announces Price Target of $39.

Benzinga Newsdesk

Attovia Therapeutics Inc

Attovia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

PRO
LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

PRO
Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

PRO
RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39

People Also Watch

People Also Watch

Attovia Therapeutics Inc

Attovia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

PROLifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

PROLeerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

PRORBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROMorgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39

People Also Watch

People Also Watch

PRO
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

PRO
LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

PRO
Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

PRO
RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

PRO
Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39